HRV as a Marker of Treatment Response in PAH Arterial Hypertension

Status Recruiting

Clinical Trial Summary

This is a prospective longitudinal cohort study to determine the value of HRV obtained using noninvasive actigraphy to quantify the response to pulmonary vasodilator therapy in newly diagnosed PAH patients

Clinical Trial Description

This single center prospective longitudinal cohort study will take place at the University of Cincinnati (UC). We will screen adult patients newly diagnosed with PAH and placed on targeted pulmonary vasodilator therapy by their treating physician for enrollment. We will enroll 35 eligible participants over a two-year period. HRV will be measured using the Polar™ H10 wearable chest actigraphy device in conjunction with analytic software to capture HRV data. After enrollment and completion of the baseline visit, study participants will receive chest actigraphy device to measure their heart rate for a two hour period twice a week during study participation. Follow up research visits will be conducted at one-month, 3-months, and 6-months to sync the actigraphy device and assess any AE's. In-between these visits, study staff will communicate with participants at two weeks, two months, 4 months, and 5 months, to identify and address any issues with study actigraphic device, assess any adverse events and maintain regular contact with study participants. Throughout study participation, subjects will continue routine clinical care at the direction of their treating physician as needed. ;

Study Design

Related Conditions & MeSH terms

Familial Primary Pulmonary Hypertension
Hypertension
Pulmonary Arterial Hypertension

Clinical Trial Details

NCT number	NCT04451850
Study type	Observational
Source	University of Cincinnati
Contact	Susan McMahan, BSN, RN, CCRP
Phone	513-558-4376
Email	susan.mcmahan@uc.edu
Status	Recruiting
Phase
Start date	June 1, 2021
Completion date	June 30, 2024

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT04076241` - Effects of Adding Yoga Respiratory Training to Osteopathic Manipulative Treatment in Pulmonary Arterial Hypertension	N/A
Completed	`NCT05521113` - Home-based Pulmonary Rehabilitation With Remote Monitoring in Pulmonary Arterial Hypertension
Recruiting	`NCT04972656` - Treatment With Ambrisentan in Patients With Borderline Pulmonary Arterial Hypertension	N/A
Completed	`NCT04908397` - Carnitine Consumption and Augmentation in Pulmonary Arterial Hypertension	Phase 1
Active, not recruiting	`NCT03288025` - Pulmonary Arterial Hypertension Improvement With Nutrition and Exercise (PHINE)	N/A
Completed	`NCT01959815` - Novel Screening Strategies for Scleroderma PAH
Recruiting	`NCT04266197` - Vardenafil Inhaled for Pulmonary Arterial Hypertension PRN Phase 2B Study	Phase 2
Active, not recruiting	`NCT06092424` - High Altitude (HA) Residents With Pulmonary Vascular Diseseases (PVD), Pulmonary Artery Pressure (PAP) Assessed at HA (2840m) vs Sea Level (LA)	N/A
Enrolling by invitation	`NCT03683186` - A Study Evaluating the Long-Term Efficacy and Safety of Ralinepag in Subjects With PAH Via an Open-Label Extension	Phase 3
Terminated	`NCT02060487` - Effects of Oral Sildenafil on Mortality in Adults With PAH	Phase 4
Terminated	`NCT02253394` - The Combination Ambrisentan Plus Spironolactone in Pulmonary Arterial Hypertension Study	Phase 4
Withdrawn	`NCT02958358` - FDG Uptake and Lung Blood Flow in PAH Before and After Treatment With Ambrisentan	N/A
Terminated	`NCT01953965` - Look at Way the Heart Functions in People With Pulmonary Hypertension (PH) Who Have Near Normal Right Ventricle (RV) Function and People With Pulmonary Hypertension Who Have Impaired RV Function. Using Imaging Studies PET Scan and Cardiac MRI.	Phase 2
Unknown status	`NCT01712997` - Study of the Initial Combination of Bosentan With Iloprost in the Treatment of Pulmonary Hypertension Patients	Phase 3
Not yet recruiting	`NCT01649739` - Vardenafil as add-on Therapy for Patients With Pulmonary Hypertension Treated With Inhaled Iloprost	Phase 4
Withdrawn	`NCT01723371` - Beta Blockers for Treatment of Pulmonary Arterial Hypertension in Children	Phase 1/Phase 2
Completed	`NCT01548950` - Drug Therapy and Surgery in Congenital Heart Disease With Pulmonary Hypertension	N/A
Completed	`NCT01165047` - Nitric Oxide, GeNO Nitrosyl Delivery System	Phase 2
Completed	`NCT00963001` - Effect of Food on the Pharmacokinetics of Oral Treprostinil	Phase 1
Completed	`NCT00902174` - Imatinib (QTI571) in Pulmonary Arterial Hypertension	Phase 3